Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study

MT Newswires Live06-17

Marinus Pharmaceuticals (MRNS) said on Monday that its experimental drug, intravenous ganaxolone, aimed at treating refractory status epilepticus - a condition where seizures persist despite standard treatments - did not achieve one of its primary goals in a Phase 3 study, sending shares down by 8.5% in premarket trading.

Marinus said IV ganaxolone did not show statistically significant results in preventing patients from progressing to IV anesthesia within 36 hours compared to placebo. However, it added that the drug did meet its other co-primary endpoint, with a statistically significant proportion of patients experiencing cessation of status epilepticus within 30 minutes of starting treatment compared to placebo.

The company said it will continue to analyze the entire dataset from the Phase 3 study and engage with the U.S. Food and Drug Administration to discuss a potential path forward for IV ganaxolone.

Marinus expects cash and cash equivalents to be sufficient to fund its operating expenses, including capital expenditures and working capital requirements, into Q2 2025.

Price: 1.3400, Change: -0.12, Percent Change: -8.53

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444166438?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-17 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444166438","market":"fut","top_or_hot":-1,"title":"Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MRNS\">Marinus Pharmaceuticals</a> (MRNS) said on Monday that its experimental drug, intravenous ganaxolone, aimed at treating refractory status epilepticus - a condition where seizures persist despite standard treatments - did not achieve one of its primary goals in a Phase 3 study, sending shares down by 8.5% in premarket trading.</p><p>Marinus said IV ganaxolone did not show statistically significant results in preventing patients from progressing to IV anesthesia within 36 hours compared to placebo. However, it added that the drug did meet its other co-primary endpoint, with a statistically significant proportion of patients experiencing cessation of status epilepticus within 30 minutes of starting treatment compared to placebo.</p><p>The company said it will continue to analyze the entire dataset from the Phase 3 study and engage with the U.S. Food and Drug Administration to discuss a potential path forward for IV ganaxolone.</p><p>Marinus expects cash and cash equivalents to be sufficient to fund its operating expenses, including capital expenditures and working capital requirements, into Q2 2025.</p><p>Price: 1.3400, Change: -0.12, Percent Change: -8.53</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-17 20:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Marinus Pharmaceuticals (MRNS) said on Monday that its experimental drug, intravenous ganaxolone, aimed at treating refractory status epilepticus - a condition where seizures persist despite standard ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNS","symbol_name":"Marinus Pharmaceuticals","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2444166438","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444166438","pubTimestamp":1718625830,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Marinus Pharmaceuticals  said on Monday that its experimental drug, intravenous ganaxolone, aimed at treating refractory status epilepticus - a condition where seizures persist despite standard treatments - did not achieve one of its primary goals in a Phase 3 study, sending shares down by 8.5% in premarket trading.Marinus said IV ganaxolone did not show statistically significant results in preventing patients from progressing to IV anesthesia within 36 hours compared to placebo. However, it added that the drug did meet its other co-primary endpoint, with a statistically significant proportion of patients experiencing cessation of status epilepticus within 30 minutes of starting treatment compared to placebo.The company said it will continue to analyze the entire dataset from the Phase 3 study and engage with the U.S. Food and Drug Administration to discuss a potential path forward for IV ganaxolone.Marinus expects cash and cash equivalents to be sufficient to fund its operating expens","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MRNS":"Marinus Pharmaceuticals"},"translate_title":"Marinus Pharmaceuticals癫痫治疗在3期研究中表现不佳","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNS":1},"content_text":"Marinus Pharmaceuticals (MRNS) said on Monday that its experimental drug, intravenous ganaxolone, aimed at treating refractory status epilepticus - a condition where seizures persist despite standard treatments - did not achieve one of its primary goals in a Phase 3 study, sending shares down by 8.5% in premarket trading.Marinus said IV ganaxolone did not show statistically significant results in preventing patients from progressing to IV anesthesia within 36 hours compared to placebo. However, it added that the drug did meet its other co-primary endpoint, with a statistically significant proportion of patients experiencing cessation of status epilepticus within 30 minutes of starting treatment compared to placebo.The company said it will continue to analyze the entire dataset from the Phase 3 study and engage with the U.S. Food and Drug Administration to discuss a potential path forward for IV ganaxolone.Marinus expects cash and cash equivalents to be sufficient to fund its operating expenses, including capital expenditures and working capital requirements, into Q2 2025.Price: 1.3400, Change: -0.12, Percent Change: -8.53","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444166438"}